PO.TB04.06 · 肿瘤生物学
Kv3.4通道在宫颈癌体外和体内模型中的差异表达:潜在的临床意义
Differential expression of the Kv3.4 channel in in vitro and in vivo models of cervical cancer: Potential clinical implications
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言:宫颈癌仍然是全球重大健康问题,而现有诊断方法存在显著局限,凸显了改进分子生物标志物的需求。其进展主要与HPV感染、雌激素暴露和离子通道失调有关。诸如Kv3.4之类的离子通道因其参与癌变过程而日益受到关注。本研究考察了Kv3.4(KCNC4)通道在宫颈癌模型中的基因和蛋白表达,并评估其药理学阻断作为潜在诊断和治疗策略的效果。
实验流程:通过qRT-PCR在HeLa和SiHa细胞中研究KCNC4基因表达,同时通过免疫细胞化学在HeLa、SiHa、正常角质形成细胞(KN)以及携带HPV16 E6/E7癌基因的角质形成细胞(KT E6E7)中评估Kv3.4蛋白。通过在使用Kv通道阻断剂BDS-I处理后进行代谢活性检测,评估Kv3.4功能抑制的效果。体内模型来自四组小鼠:经17β-雌二醇处理的转基因K14E7小鼠(K14E7+E2)、未处理的K14E7小鼠、经17β-雌二醇处理的非转基因FvB小鼠(FvB+E2),以及未处理的FvB对照,通过免疫组织化学检测HPV癌基因和雌激素暴露对宫颈上皮中Kv3.4调控的影响。
结果:基因表达分析显示,与SiHa细胞相比,HeLa细胞中KCNC4表达显著更高,这与它们不同的HPV拷贝数一致。免疫细胞化学证实了Kv3.4蛋白在HeLa、SiHa和KT E6E7细胞中表达,而在KN细胞中不表达。BDS-I处理仅在KT E6E7细胞中显著降低代谢活性,对KN细胞无影响。在小鼠宫颈组织中,Kv3.4表达在FvB+E2小鼠中最强,其次为4个月时的K14E7和未处理的FvB。在7个月时,表达仍以FvB+E2最高,其次为K14E7+E2、K14E7和FvB,表明雌激素暴露和HPV癌基因在体内增强了Kv3.4表达。
结论:我们的研究结果表明,Kv3.4通道与HPV相关的宫颈癌变有关。在HeLa、SiHa、KT E6E7以及来自FvB+E2、K14E7+E2和K14E7小鼠的宫颈组织中均检测到Kv3.4蛋白,表明雌激素和HPV癌基因在体内上调该通道。值得注意的是,Kv3.4阻断选择性地降低了KT E6E7细胞的增殖,提示HPV转染的角质形成细胞对该通道具有更强的依赖性。总体而言,这些结果支持Kv3.4作为早期HPV介导宫颈癌的潜在生物标志物和治疗靶点。本研究部分由Conacyt资助(授予JdlG的A1-S-9783基金)。
查看英文原文 English abstract
Introduction: Cervical cancer remains a major global health concern, and current diagnostic methods have significant limitations, highlighting the need for improved molecular biomarkers. Its progression is primarily linked to HPV infection, estrogen exposure, and ion channel deregulation. Ion channels such as Kv3.4 have gained relevance due to their involvement in carcinogenesis. This study examines the gene and protein expression of the Kv3.4 (KCNC4) channel in cervical cancer models and evaluates the effects of its pharmacological blockade as a potential diagnostic and therapeutic strategy.
Experimental procedure: KCNC4 gene expression was study in HeLa and SiHa cells by qRT-PCR, while Kv3.4 protein was evaluated by immunocytochemistry in HeLa, SiHa, normal keratinocytes (KN) and keratinocytes with HPV16 E6/E7 oncogenes (KT E6E7). The effect of Kv3.4 functional inhibition was assessed by metabolic activity assays following treatment with the Kv channel blocker BDS-I. In vivo model from four mouse groups: transgenic K14E7 mice treated with 17beta-estradiol (K14E7+E2), untreated K14E7 mice, non-transgenic FvB mice treated with 17beta-estradiol (FvB+E2), and untreated FvB controls, were examined by immunohistochemistry to determine the impact of HPV oncogenes and estrogen exposure on Kv3.4 regulation in cervical epithelium.
Results: Gene expression analysis showed a significantly higher KCNC4 expression in HeLa cells compared with SiHa cells, consistent with their differing HPV copy numbers. Immunocytochemistry confirmed Kv3.4 protein expression in HeLa, SiHa, and KT E6E7 cells, but not in KN cells. BDS-I treatment significantly reduced metabolic activity only in KT E6E7 cells, with no effect in KN cells. In mouse cervical tissues, Kv3.4 expression was strongest in FvB+E2 mice, followed by K14E7 and untreated FvB at 4 months. At 7 months, expression remained highest in FvB+E2, then K14E7+E2, K14E7, and FvB, indicating that estrogen exposure and HPV oncogenes enhance Kv3.4 expression in vivo.
Conclusion. Our findings show that the Kv3.4 channel is linked to HPV-related cervical carcinogenesis. Kv3.4 protein was detected in HeLa, SiHa, KT E6E7, and in cervical tissues from FvB+E2, K14E7+E2, and K14E7 mice, indicating that estrogen and HPV oncogenes upregulate the channel in vivo. Notably, Kv3.4 blockade selectively reduced proliferation in KT E6E7 cells, suggesting a greater dependence of HPV-transfected keratinocytes on this channel. Overall, these results support Kv3.4 as a potential biomarker and therapeutic target in early HPV-mediated cervical cancer. Partially supported by Conacyt grant A1-S-9783 to JdlG.
利益披露 Disclosure
A. A. Ramirez, None..
A. J. Chiliquinga, None..
I. Ogonaga-Borja, None..
B. Acosta, None..
P. Gariglio, None..
R. Ocádiz-Delgado, None..
J. de la Garza, None..
E. Hernández-Gallegos, None..
M. Chávez-López, None..
J. Noyola, None..
J. Camacho, None.